Leflunomide reversed chronic renal allograft dysfunction in a prospective pilot study reported in the October issue of the American Journal of Transplantation.
“Leflunomide is an attractive immunosuppressant agent for transplantation because of its low side-effect profile, antiviral properties, and mediation of both cellular and humoral immunities,” write Karen L. Hardinger and colleagues from Washington University in St. Louis, Missouri.
In this open-label, crossover trial, 22 renal transplant recipients were converted from azathioprine or mycophenolate mofetil to leflunomide in hopes of slowing progression of deteriorating renal function in five patients, cyclosporine nephrotoxicity in four, or chronic allograft nephropathy in 13. Patients continued maintenance immunosuppressive therapy, including cyclosporine and prednisone.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!